News-arkiv - Page 4 of 25 - Isofol Medical

Isofol successfully completes pre-IND meeting with the FDA for arfolitixorin

GOTHENBURG, Sweden, July 16, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully […]

GOTHENBURG, Sweden, 4 July 2025 – Isofol Medical AB (“Isofol” or the “Company”) today announces the outcome of the Company’s

GOTHENBURG, Sweden, 17 June 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (”Isofol” or

GOTHENBURG, Sweden, June 12, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed

GOTHENBURG, 11 June 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its extra ordinary general meeting today at

GOTHENBURG, Sweden, 5 June 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol” or

GOTHENBURG, Sweden, June 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company is participating

GOTHENBURG, Sweden, June 2, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has been

GOTHENBURG, May 21, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its annual general meeting (the “AGM”) today

GOTHENBURG, Sweden, May 21, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report